Albendazole treatment of pulmonary hydatid cysts in naturally infected sheep: a study with relevance to the treatment of hydatid cysts in man

DL MORRIS, MJ CLARKSON, MF STALLBAUMER, J PRITCHARD, RS JONES, JB CHINNERY

From the Department of Surgery, University Hospital, Nottingham; the Department of Veterinary Clinical Science, Division of Farm Animal Medicine, Veterinary Field Station, University of Liverpool; and the Department of Anaesthesia, Royal Liverpool Hospital, Liverpool

ABSTRACT Albendazole was given orally to sheep with naturally occurring live pulmonary and hepatic cysts. The viability of pulmonary cysts was established before treatment by thoracotomy and needle puncture. Both 10 and 20 mg/kg/day doses were found effective in that no viable protoscoleces were found after six weeks' treatment in either group while untreated controls still had viable cysts. In addition, treated animals showed macroscopic and electron microscopic changes. Bone marrow toxicity probably occurred in two sheep.

Hydatid disease in man is caused by infection with Echinococcus granulosus or E multilocularis and usually presents with symptoms from hepatic or pulmonary cysts. It is a widespread problem throughout the world and until recently the only effective treatment was surgical excision. Mebendazole was the first drug shown to be of benefit in animals, and early clinical results were encouraging. Other patients have failed to benefit despite prolonged high dose treatment. Mebendazole is an extremely insoluble and therefore poorly absorbed drug and the variable clinical results may correlate with blood concentrations. Concentrations of the metabolites of mebendazole (methyl 5-(hydroxybenzyl)-2-benzimidazole carbamate and 2-amino-5-benzimidazole) are higher, but these metabolites are not thought to have potent anthelmintic activity (H Vanden Bosch, personal communication).

Albendazole (Smith, Kline, and French) is partly absorbed (less than 0.4% of a 400 mg oral dose) and is rapidly converted into three principal metabolites: sulphoxide, sulphone, and 2-aminosulphone, the first of which is probably responsible for the anthelmintic activity of the drug. Maximum serum concentrations of about 0.3 µg/ml albendazole sulphoxide may be expected in sheep one to three hours after a single oral dose of 10 mg/kg.

The relative efficacy of these metabolites or those of mebendazole for the treatment of human hydatid disease are not yet known.

Early clinical and radiographic results with albendazole in human hydatid disease are promising. Initial results with mebendazole were, however, encouraging and even computed tomographic evidence of cyst regression after albendazole treatment does not constitute absolute proof of therapeutic action, because spontaneous regression of hydatid disease does occasionally occur. Similarly, it is not possible in man to be sure that a given cyst is viable before treatment, as needle aspiration is contraindicated because of the hazard of anaphylaxis and the risk of dissemination due to implantation of spilled protoscoleces.

The use of rodent models with peritoneal hydatid disease is probably of little relevance to the treatment of hepatic and pulmonary cysts in man because the peritoneal cysts have extremely thin walls with virtually no ectocyst layer. We have used sheep with naturally occurring hydatid cysts as a model to assess the value of albendazole in the treatment of hydatid disease in man. The model is similar to that of Gemmell et al but has been improved in that sheep were selected by radiography and in addition, in the second phase of the study, by confirming viability of...
the cysts by needle puncture at thoracotomy before the start of drug treatment.

**Methods**

Welsh Cross ewes were purchased from two farms in mid Wales where the dogs had been shown to be infected with *E granulosus*. The ewes were culled because they were very thin owing to tooth disease and loss. They had lived on the farms for at least six years.

The sheep had chest radiography and those with large uncalcified cysts (which previous experience had indicated were likely to be viable) were selected, according to a previously described technique. In the first phase, four sheep were treated with oral albendazole (SK and F, Valbazen) at 20 mg/kg/day for five days of each week in a single oral dosage. Treatment was continued for six weeks, and necropsy was performed at death or on completion of treatment. The cysts were examined and were then aspirated to obtain protoscoleces, which were observed under a microscope immediately for flame cell activity and then tested for their ability to exclude 5% aqueous eosin.

In the second phase of the study, 10 sheep with radiographic evidence of large pulmonary cysts underwent thoracotomy. Anaesthesia was induced with pentobarbitone sodium and maintained with nitrous oxide/oxygen and halothane, an East Radcliffe ventilator being used. The cysts were aspirated with a 21 G needle and 1–2 ml of fluid removed; this was reinjected and withdrawn or the cyst shaken to suspend any protoscoleces contained in the cyst. These protoscoleces were then examined for viability. If aspiration of the first cyst confirmed viability no further cysts were punctured, but if the first cyst was not viable further cysts were examined. The use of intercostal tube drains was judged impractical, but the size of any pneumothorax was minimised by fully inflating the lungs during the final parts of the chest closure. In two sheep no viable protoscoleces were found and they were excluded from the study. Of the remaining eight sheep, six were treated at 10 mg/kg/day for six weeks and two sheep remained untreated. All sheep underwent necropsy at death or at the completion of treatment.

In addition to the viability tests described for phase 1, segments of germinal membrane were examined by electron microscopy. During treatment haemoglobin, total and differential white cell counts, and serum sorbitol dehydrogenase activity were measured weekly in phase 2 of the study. Finally, a further four sheep with live cysts remained as untreated controls for six weeks after thoracotomy and then underwent necropsy.
Albendazole treatment of pulmonary hydatid cysts in naturally infected sheep

Cyst numbers and sites in phase 2 of the study

<table>
<thead>
<tr>
<th>Sheep No</th>
<th>Site and No of cysts</th>
<th>Treatment</th>
<th>Necropsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>329</td>
<td>Lung 2, Liver 15</td>
<td>Alb 10 mg/kg per day</td>
<td>Little fluid, infected</td>
</tr>
<tr>
<td>322</td>
<td>Lung 5, Liver 10</td>
<td>Nil</td>
<td>Tense, clear fluid; viable protoscoleces</td>
</tr>
<tr>
<td>298</td>
<td>Lung 7, Liver 6</td>
<td>Nil</td>
<td>Tense, clear fluid; viable protoscoleces</td>
</tr>
<tr>
<td>222</td>
<td>Liver 3</td>
<td>Nil</td>
<td>Tense, clear fluid; viable protoscoleces</td>
</tr>
<tr>
<td>285</td>
<td>Lung 1</td>
<td>Nil</td>
<td>Tense, clear fluid; viable protoscoleces</td>
</tr>
<tr>
<td>327</td>
<td>Cysts not viable—excluded from study</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Alb—albendazole.

Results

PHASE 1
The macroscopic appearance of cysts in the treated sheep at necropsy differed from their usual appearance in that they were flaccid and contained little fluid. Instead of the crystal clear fluid seen in viable cysts the fluid was yellowish and clotted when allowed to stand, suggesting an increase in protein content. All protoscoleces in the treated sheep appeared dead (there was no motility or flame cell activity and all stained with aqueous eosin). One sheep treated with albendazole in a dose of 20 mg/kg/day died after four weeks' treatment of *Pasteurella septicaemia*. Cysts visible on chest radiographs are shown in figure 1.

PHASE 2
The sheep tolerated thoracotomy well despite their age and poor condition. The results are summarised in the table. One of the treated sheep (No 322) died after five and a half weeks of treatment with acute pneumonia, but no organisms were grown from the lungs or blood. Considerable reductions in total white cell count and polymorph count were seen in this sheep (fig 2), but there was no such effect in the remaining five animals. There were no significant differences in the serum sorbitol dehydrogenase activity of the treated and untreated sheep, this enzyme being a good measure of hepatic cell damage in sheep. In the treated sheep many protoscoleces were present but no viable protoscoleces were seen, all being shrunken, immotile, and staining with eosin. Gerbil intraperitoneal injections of protoscoleces from the treated sheep failed to show any evidence of viability. Cysts that had been punctured earlier did not differ in appearance from those that had not been punctured, except for the pleural adhesions to the former that were frequently found. Hepatic cysts were also flaccid and contained yellow fluid and dead protoscoleces. Several cysts of 5–10 cm in diameter were seen and all appeared dead.

The control sheep, which had thoracotomy and confirmation of the viability of cysts but received no albendazole, still had viable protoscoleces within tense cysts containing clear fluid at necropsy,
whether the cyst had been punctured previously or not. Electron microscopy of the germinal membranes and laminated membrane showed severe degeneration affecting all areas of the germinal membrane in the treated sheep (fig 3) but intact membranes in the controls (fig 4).

The last four control sheep were found to have multiple viable pulmonary and hepatic cysts at necropsy.

Discussion

The chemotherapy of human hydatid disease could be of great importance in patients with inoperable cysts or multiple cysts and in those unfit for surgery or perhaps suffering from recurrent disease, where operative mortality is higher. Similarly, effective chemotherapy would be a major breakthrough in the treatment of *E multilocularis*, which is almost invariably fatal; and albendazole would be worth a trial. While patients with cysts due to *E granulosus* who have been treated with albendazole have shown both clinical and radiographic evidence of response, neither type of response is direct evidence of efficacy, for cysts may have already been dead or have been in the process of spontaneous disappearance.

We have used adult sheep with naturally occurring pulmonary and hepatic hydatid disease as this closely simulates the disease seen in man. In particular, a rodent peritoneal cyst model would seem very different from the cysts seen in man. Our results are extremely encouraging in that no viable proto-
scolecites were seen in any of the treated animals, the cysts appeared flaccid, and the laminated and ger-
minal membrane had separated from the host ecto-
cyst. This separation was noted on computed tomo-
graphy and ultrasound scanning in some patients
having albendazole treatment.\textsuperscript{12} The degenerate
remnants of the germinal membranes seen by elec-
tron microscopy support the data on viability and macroscopic appearance and are similar to those
seen with mebendazole in a rodent peritoneal
model.\textsuperscript{18}

Bone marrow depression probably played a con-
tributory part in the death of two treated ewes; but
no such problem has been encountered in man. This
may be related to two factors other than interspecies
variation. The albendazole was given to the sheep in
a single daily dose, thus producing much higher peak
concentrations, which would be accentuated by the
increased absorption that occurs in sheep. Mean
peak serum concentrations of albendazole sulphox-
ide and sulphone in sheep after a single daily dose of
10 mg/kg of albendazole are of the order of 3.2 and
0.9 μg/ml respectively, which is several times higher
than those achieved in man.\textsuperscript{1} Neutropenia has been
reported during mebendazole treatment of hydatid
disease in man,\textsuperscript{14} but our experience of bone marrow
depression in animals with albendazole has not yet
been reflected in man. This difference in dosage and

\textbf{Fig 4}  
*Electron micrographs of germinal membrane from an untreated control sheep showing viable membrane.*
pharmacokinetics must also be considered when taking into account the apparently excellent efficacy of albendazole in this model at doses of both 10 and 20 mg/kg/day. Possibly the lower peak concentrations, due to poorer absorption, and the divided dosage used in man will not be as effective as in sheep, where there are good data on the efficacy of the drug in a similar sheep model; but this drug has been less effective in clinical practice. We considered it important, however, first to decide whether albendazole was effective; the optimal dosage required in man can now receive further attention.

Thus albendazole in a single daily dosage of 10 or 20 mg/kg was effective in killing protoscoleces and the germinal membrane in pulmonary hydatid cysts of proved viability in adult sheep with naturally occurring disease. These data support the belief that albendazole may exert a therapeutic action in hydatid disease in man, but careful monitoring of the white cell count during human treatment is advised.

We are most grateful to the overseas medical division and the veterinary division of Smith, Kline, and French for financial support and for supplies of albendazole. We are grateful to our colleagues at the Veterinary Field Station for their generous help and particularly for radiographic and haematological examinations. We also acknowledge the care and attention given to the sheep by Helen Michell and Janette Perry. We are grateful to Professor D Turner and Mr S Terrace, Department of Pathology, University of Nottingham, for the electron microscopy studies and to Theresa Borowska for typing the manuscript.

References

Albendazole treatment of pulmonary hydatid cysts in naturally infected sheep: a study with relevance to the treatment of hydatid cysts in man.

D L Morris, M J Clarkson, M F Stallbaumer, J Pritchard, R S Jones and J B Chinnery

Thorax 1985 40: 453-458
doi: 10.1136/thx.40.6.453

Updated information and services can be found at:
http://thorax.bmj.com/content/40/6/453

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/